Description

The genotypes of the animals provided may not reflect those discussed in the strain description or the mating scheme utilized by The Jackson Laboratory prior to cryopreservation. Please inquire for possible genotypes for this specific strain.

Strain Information

Type Congenic; Mutant Strain; Targeted Mutation; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Additional information on Congenic nomenclature. Species laboratory mouse Background Strain C3H/HeJ Donor Strain B6;129P-Il2tm1Hor (129P2 derived E14TG2a ES cell line) Generation N10F16N1   Donating Investigator Ivan Horak,   Forschungs institut fur Molekulare

Appearance
agouti
Related Genotype: A/A

Description
Homozygous mutant mice for the Il2^tm1Hor targeted mutation show no apparent deficit in thymocyte differentiation or selection, types and numbers of T cells from spleens and lymph nodes are comparable to those of wildtype. They do have an impaired response to polyclonal T cell activators in the absence of additional IL2, deficits in their helper function and a reduction in natural killer cell activity. There is significant pre-weaning and post-weaning loss of homozygotes on the C3H/HeJCrlBR and C57BL/6J genetic backgrounds. In addition, homozygous mice develop inflammatory bowel disease between 6 and 15 weeks of age and reportedly die within 10-25 weeks under conventional housing conditions. Homozygotes on the C57BL/6J genetic background show an atrophied pancreas with apparently intact islets. Homozygotes on the BALB/c genetic background do not develop inflammatory bowel disease symptoms but rather die 3-5 weeks postnatally of a form of hemolytic anemia. For a more detailed description please refer to the JAX Notes Fall 1996 article.

Control Information

	Control
	Wild-type from the colony
	000659 C3H/HeJ
Considerations for Choosing Controls

Related Strains

Strains carrying   Il2^tm1Hor allele

002252	B6.129P2-Il2tm1Hor/J
002229	C.129P2(B6)-Il2tm1Hor/J
002573	NOD.129P2(B6)-Il2tm1Hor/DvsJ

View Strains carrying   Il2^tm1Hor     (3 strains)

Strains carrying other alleles of Il2

006102	B10.Cg-H2k Tg(Il2/NFAT-luc)83Rinc/J
006098	B6.Cg-Tg(Il2/NFAT-luc)83Rinc/J

View Strains carrying other alleles of Il2     (2 strains)

Additional Web Information

Congenic Nomenclature
JAX^® NOTES, Fall 1996; 467. Il2^tm1Hor, an Interleukin-2 Gene Targeted Mutation.

Phenotype

Phenotype Information

View Related Disease (OMIM) Terms

Related Disease (OMIM) Terms

Inflammatory Bowel Disease 1; IBD1 - Models with phenotypic similarity to human disease where etiologies are distinct.2

2 Human genes are associated with this disease. Orthologs of those genes do not appear in the mouse genotype(s).

View Mammalian Phenotype Terms

Mammalian Phenotype Terms

      assigned by genotype

Il2^tm1Hor/Il2^tm1Hor

        C3.129P2-Il2^tm1Hor

• hematopoietic system phenotype
• increased CD4-positive T cell number (MGI Ref ID J:28924)
  • activated T cell numbers fail to decrease to normal levels after immunization with staphylococcal enterotoxin, indicating a problem with peripheral deletion
• increased CD8-positive T cell number (MGI Ref ID J:28924)
  • activated T cell numbers decrease with slower kinetics than wild-type mice after after immunization with staphylococcal enterotoxin
• immune system phenotype
• increased CD4-positive T cell number (MGI Ref ID J:28924)
  • activated T cell numbers fail to decrease to normal levels after immunization with staphylococcal enterotoxin, indicating a problem with peripheral deletion
• increased CD8-positive T cell number (MGI Ref ID J:28924)
  • activated T cell numbers decrease with slower kinetics than wild-type mice after after immunization with staphylococcal enterotoxin

The following phenotype information may relate to a genetic background differing from this JAX^® Mice strain.

Il2^tm1Hor/Il2^tm1Hor

        involves: 129P2/OlaHsd * C57BL/6

• life span-post-weaning/aging
• premature death (MGI Ref ID J:15223)
  • about of 50% of mice die within the first 9 weeks of age with enlarged lymphoid organs and severe anemia
  • the remaining mice die by 25 weeks of age from inflammatory bowel disease
• digestive/alimentary phenotype
• abnormal intestinal epithelium morphology (MGI Ref ID J:15223)
  • prominent epithelial regeneration with crypt branching and dysplasia near areas of inflammation
  • crypt hyperplasia and unusual branching is observed
• abnormal intestinal goblet cells (MGI Ref ID J:15223)
  • colon epithelium shows loss of goblet cells
  • loss of mucin is observed in goblet cells
• crypts of Lieberkuhn abscesses (MGI Ref ID J:15223)
  • frequently occurres in the large intestine
• intestinal ulcer (MGI Ref ID J:15223)
  • ulcers occur in the large intestine, with pronounced thickening of the bowel wall
• colitis (MGI Ref ID J:15223)
  • all mice that do not die within the first 9 weeks after birth develop an inflammatory bowel disease that is similar to the human disease ulcerative colitis
  • infiltrating lymphocytes sometimes form nodules
  • mice bred in a germ-free facility do not display any histopathological signs of colitis
  • mice bred under specific pathogen free conditions do not develop any clinical signs of colitis but histological and immunological examinations show the beginning of inflammatory processes in mice that are 17-20 weeks of age
  • occurs in all mice that survive past 9 weeks of age, with thickening of large intestinal wall
  • mice kept under a specific pathogen free environment develop colitis when immunized with an antigen that activates CD4 T cells
• diarrhea (MGI Ref ID J:29999)
  • occurs in mice 24 weeks of age
• chronic diarrhea (MGI Ref ID J:15223)
  • all mice that do not die within the first 9 weeks after birth exhibit diarrhea
• rectal hemorrhage (MGI Ref ID J:29999)
  • rarely observed
• rectal prolapse (MGI Ref ID J:29999)
  • occasional occurrence among mice whom live past 9 weeks of age
  • frequent occurrence among mice whom live past 9 weeks of age
• immune system phenotype
• abnormal immune system organ morphology (MGI Ref ID J:79241)
  • proliferative response of splenocytes to anti-CD3 antibody is only 16% of wt controls
  • poor proliferative response to anti-CD3 antibody is partially rescued by addition of cytokines including IL-2, IL-4, IL-7
  • there is reduced proliferation to allogenic leukocytes
• enlarged lymph nodes (MGI Ref ID J:15223)
• lymph node hyperplasia (MGI Ref ID J:16662)
• enlarged mesenteric lymph nodes (MGI Ref ID J:29999)
  • increased 3-10 fold in size as compared to control littermates
• enlarged spleen (MGI Ref ID J:15223)
  • occurs in the 50% of mice that die prematurely
• abnormal lymphocyte morphology (MGI Ref ID J:37220)
  • decreased apoptosis in thymus upon injection with anti-CD3 antibody
• abnormal CD8 positive, alpha-beta intraepithelial T cell morphology (MGI Ref ID J:15223)
  • increased number (5-100 fold) are found in diseased colon
  • T cells expressing the CD8 alpha-beta heterodimer predominate over CD8 alpha-alpha T cells
• abnormal T-helper 1 cell differentiation (MGI Ref ID J:37220)
  • 10 fold greater amounts of IFN gamma were made by thymocytes from immunized mutant mice as measured by an in vitro assay
  • low levels of the Th2 cytokine IL-4 were made compared to the large level made by wt thymocytes
  • however, treatment with an IL-12 neutralizing antibody normalized Th1cytokine levels
• abnormal class switch recombination (MGI Ref ID J:15573)
  • there is delayed class switching from IgM to IgG after infection with vesicular stomatitis virus
• abnormal gamma-delta intraepithelial T cell morphology (MGI Ref ID J:15223)
  • decreased percentage of these cells are found in the colon epithelium
• abnormal lymphocyte cell number (MGI Ref ID J:15223)
• decreased double-negative T cell number (MGI Ref ID J:15223)
  • there is a drastic reduction in the colon
• decreased double-positive T cell number (MGI Ref ID J:37220)
  • percentage of these cells is decreased (47.0% vs 86.2%) in the thymus when mice are immunized with a CD4 T cell activating antigen
• increased double-negative T cell number (MGI Ref ID J:37220)
  • percentage of these cells is increased (11.2% vs 3.7%) in the thymus when mice are immunized with a CD4 T cell activating antigen
• increased pre-B cell number (MGI Ref ID J:16662)
  • of cells in the bone marrow
• increased single-positive T cell number (MGI Ref ID J:37220)
  • percentage of these cells is increased (41.8% vs 20.9.2%) in the thymus when mice are immunized with a CD4 T cell activating antigen
  • however, treatment with an IL-12 neutralizing antibody normalized SP cell numbers
• abnormal thymocyte activation (MGI Ref ID J:37220)
  • increased activation of thymocytes 7 days after immunization with a CD4 T cell activating antigen, as measured by expression of CD69 and Icam1
  • however, treatment with an IL-12 neutralizing antibody normalized the percentage of activated thymocytes
  • in vitro proliferation is reduced in presence of concanavalin A or anti-CD3 antibody
• decreased T cell proliferation (MGI Ref ID J:26198)
• increased B cell proliferation (MGI Ref ID J:16662)
  • B cells from lymph nodes have a larger size and incorporate more BrdU, indicating a faster proliferation rate
• increased T cell proliferation (MGI Ref ID J:15223)
  • the proliferation of T cells in the colon is twice that of wild-type controls
  • 2-10 fold higher using in vivo incorporation of BrdU, which indicates a faster proliferation rate
• increased pro-B cell number (MGI Ref ID J:16662)
  • of cells in the bone marrow
• abnormal lymphocyte physiology (MGI Ref ID J:15223)
• abnormal CD4-positive T cell physiology (MGI Ref ID J:15573)
  • there is an impaired ability to induce Ig class switching in B cells after infection with vesicular stomatitis virus
  • increased cytotoxic effectiveness of CD4 T cells isolated from the colon
  • unable to induce IgM secretion from activated B cells in an in vitro assay
  • however, IgM levels are in vivo are normal
• abnormal class switch recombination (MGI Ref ID J:15573)
  • there is delayed class switching from IgM to IgG after infection with vesicular stomatitis virus
• abnormal cytotoxic T cell physiology (MGI Ref ID J:39981)
  • enhanced target cell killing by intraepithelial lymphocytes T cells (IEL) and lamina propia lymphocytes of the large intestine
  • enhanced target cell killing by intraepithelial lymphocytes T cells (IEL) of the small intestine
• defective cytotoxic T cell cytolysis (MGI Ref ID J:15573)
  • there is a three fold reduction of target cell killing by primary T cells in a chromium release assay
  • no target cell killing by previously stimulated T cells in a chromium release assay
  • there is reduced killing of allogeneic tumor cells in an in vitro assay
  • footpad swelling is reduced 6-10 days after infection with lymphocytic choriomeningitis virus
• abnormal level of surface class II molecules (MGI Ref ID J:15223)
  • expression occurs in high number of colon epithelial cells
• abnormal thymocyte activation (MGI Ref ID J:37220)
  • increased activation of thymocytes 7 days after immunization with a CD4 T cell activating antigen, as measured by expression of CD69 and Icam1
  • however, treatment with an IL-12 neutralizing antibody normalized the percentage of activated thymocytes
  • in vitro proliferation is reduced in presence of concanavalin A or anti-CD3 antibody
• decreased T cell proliferation (MGI Ref ID J:26198)
• impaired NK cell cytolysis (MGI Ref ID J:15573)
  • 3 to 9 fold reduction in killing of NK susceptible target cells as measured by chromium release assay
• increased B cell proliferation (MGI Ref ID J:16662)
  • B cells from lymph nodes have a larger size and incorporate more BrdU, indicating a faster proliferation rate
• increased IgA level (MGI Ref ID J:15223)
  • drastic elevation in secretion by B cells found in the colon
• increased IgE level (MGI Ref ID J:16662)
  • levels are 10 fold higher than those observed in wild-type mice
• increased IgG1 level (MGI Ref ID J:15223)
  • drastic elevation in secretion of IgG1 by B cells found in the colon
  • levels of IgG1 are increased 100 fold
  • levels of IgG1 are drastically increased to levels above 2700 ug/ml
• increased IgG2a level (MGI Ref ID J:16662)
  • levels of IgG2a are also elevated
• increased IgG2b level (MGI Ref ID J:16662)
  • levels of IgG2b are also elevated
• increased T cell proliferation (MGI Ref ID J:15223)
  • the proliferation of T cells in the colon is twice that of wild-type controls
  • 2-10 fold higher using in vivo incorporation of BrdU, which indicates a faster proliferation rate
• colitis (MGI Ref ID J:15223)
  • all mice that do not die within the first 9 weeks after birth develop an inflammatory bowel disease that is similar to the human disease ulcerative colitis
  • infiltrating lymphocytes sometimes form nodules
  • mice bred in a germ-free facility do not display any histopathological signs of colitis
  • mice bred under specific pathogen free conditions do not develop any clinical signs of colitis but histological and immunological examinations show the beginning of inflammatory processes in mice that are 17-20 weeks of age
  • occurs in all mice that survive past 9 weeks of age, with thickening of large intestinal wall
  • mice kept under a specific pathogen free environment develop colitis when immunized with an antigen that activates CD4 T cells
• increased length of allograft survival (MGI Ref ID J:26198)
  • graft rejection of allogeneic pancreatic islet cells is delayed by 11 days compared to controls
• increased susceptibility to viral infection (MGI Ref ID J:26861)
  • despite reduced cytotoxic T cell activity, mice still clear lymphocytic choriomeningitis virus within nine days of infection
• other phenotype
• amyloidosis (MGI Ref ID J:15223)
  • predominately in liver, spleen, and kidneys
• growth/size phenotype
• cachexia (MGI Ref ID J:29999)
  • weight loss resulting from intestinal inflammation is observed by 24 weeks
• hematopoietic system phenotype
• abnormal lymphocyte morphology (MGI Ref ID J:37220)
  • decreased apoptosis in thymus upon injection with anti-CD3 antibody
• abnormal CD8 positive, alpha-beta intraepithelial T cell morphology (MGI Ref ID J:15223)
  • increased number (5-100 fold) are found in diseased colon
  • T cells expressing the CD8 alpha-beta heterodimer predominate over CD8 alpha-alpha T cells
• abnormal T-helper 1 cell differentiation (MGI Ref ID J:37220)
  • 10 fold greater amounts of IFN gamma were made by thymocytes from immunized mutant mice as measured by an in vitro assay
  • low levels of the Th2 cytokine IL-4 were made compared to the large level made by wt thymocytes
  • however, treatment with an IL-12 neutralizing antibody normalized Th1cytokine levels
• abnormal class switch recombination (MGI Ref ID J:15573)
  • there is delayed class switching from IgM to IgG after infection with vesicular stomatitis virus
• abnormal gamma-delta intraepithelial T cell morphology (MGI Ref ID J:15223)
  • decreased percentage of these cells are found in the colon epithelium
• abnormal lymphocyte cell number (MGI Ref ID J:15223)
• decreased double-negative T cell number (MGI Ref ID J:15223)
  • there is a drastic reduction in the colon
• decreased double-positive T cell number (MGI Ref ID J:37220)
  • percentage of these cells is decreased (47.0% vs 86.2%) in the thymus when mice are immunized with a CD4 T cell activating antigen
• increased double-negative T cell number (MGI Ref ID J:37220)
  • percentage of these cells is increased (11.2% vs 3.7%) in the thymus when mice are immunized with a CD4 T cell activating antigen
• increased pre-B cell number (MGI Ref ID J:16662)
  • of cells in the bone marrow
• increased single-positive T cell number (MGI Ref ID J:37220)
  • percentage of these cells is increased (41.8% vs 20.9.2%) in the thymus when mice are immunized with a CD4 T cell activating antigen
  • however, treatment with an IL-12 neutralizing antibody normalized SP cell numbers
• abnormal thymocyte activation (MGI Ref ID J:37220)
  • increased activation of thymocytes 7 days after immunization with a CD4 T cell activating antigen, as measured by expression of CD69 and Icam1
  • however, treatment with an IL-12 neutralizing antibody normalized the percentage of activated thymocytes
  • in vitro proliferation is reduced in presence of concanavalin A or anti-CD3 antibody
• decreased T cell proliferation (MGI Ref ID J:26198)
• increased B cell proliferation (MGI Ref ID J:16662)
  • B cells from lymph nodes have a larger size and incorporate more BrdU, indicating a faster proliferation rate
• increased T cell proliferation (MGI Ref ID J:15223)
  • the proliferation of T cells in the colon is twice that of wild-type controls
  • 2-10 fold higher using in vivo incorporation of BrdU, which indicates a faster proliferation rate
• increased pro-B cell number (MGI Ref ID J:16662)
  • of cells in the bone marrow
• anemia (MGI Ref ID J:15223)
  • severe anemia is found in 50% of mice that die prematurely
  • occurs in mice 24 weeks of age
• enlarged spleen (MGI Ref ID J:15223)
  • occurs in the 50% of mice that die prematurely
• endocrine/exocrine gland phenotype
• crypts of Lieberkuhn abscesses (MGI Ref ID J:15223)
  • frequently occurres in the large intestine
• behavior/neurological phenotype
• hunched posture (MGI Ref ID J:29999)
  • occurs in mice 24 weeks of age
• cardiovascular system phenotype
• rectal hemorrhage (MGI Ref ID J:29999)
  • rarely observed

Il2^tm1Hor/Il2^tm1Hor

        C.129P2-Il2^tm1Hor

• life span-post-weaning/aging
• premature death (MGI Ref ID J:29799)
  • mice all die by 5 weeks of age, compared to death by 25 weeks of age for mice homozygous for the same mutant locus on a B6.129P2 background mice all die by 5 weeks of age, compared to death by 25 weeks of age for mice with the same mutant locus on a mixed genetic background
• immune system phenotype
• abnormal lymphocyte morphology (MGI Ref ID J:29799)
• increased B cell proliferation (MGI Ref ID J:29799)
  • faster proliferation as measured by BrdU incorporation
• increased T cell proliferation (MGI Ref ID J:29799)
  • by 10 days of age, T cells in lymph nodes express high levels of activation markers and are proliferating at an increased rate
  • CD4 T cells are activated prior to CD8 T cells (10 days vs. 15 days of age)
• increased germinal center B cell number (MGI Ref ID J:29799)
• increased plasma cell number (MGI Ref ID J:29799)
  • seen in the spleen by 15 days of age
• abnormal regulatory T cell physiology (MGI Ref ID J:112603)
  • there is a rapid loss of adoptively transferred regulatory T cells
• abnormal spleen morphology (MGI Ref ID J:29799)
• increased spleen red pulp amount (MGI Ref ID J:29799)
• spleen hyperplasia (MGI Ref ID J:29799)
  • 15 day old mice exhibit hyperplasia of the white pulp
• enlarged lymph nodes (MGI Ref ID J:29799)
• increased IgG level (MGI Ref ID J:29799)
  • increased level of IgG secreting B cells from spleen and lymph nodes
• increased inflammatory response (MGI Ref ID J:29799)
• heart inflammation (MGI Ref ID J:29799)
  • moderate to severe inflammation noted upon necropsy
• liver inflammation (MGI Ref ID J:29799)
• lung inflammation (MGI Ref ID J:29799)
  • moderate to severe inflammation noted upon necropsy
• pancreas inflammation (MGI Ref ID J:29799)
  • moderate to severe inflammation noted upon necropsy
• vasculitis (MGI Ref ID J:29799)
  • moderate to severe inflammation noted in the major thoracic blood vessels upon necropsy
• increased susceptibility to autoimmune hemolytic anemia (MGI Ref ID J:29799)
  • cause of death for mice on this genetic background, as opposed to death caused by inflammatory bowel disease for homozygous mice on a B6.129P2 genetic background
• hematopoietic system phenotype
• abnormal bone marrow cell number (MGI Ref ID J:29799)
  • invasion of T cells occur, with a concurrent drop in B cells and other nucleated cells
• abnormal lymphocyte morphology (MGI Ref ID J:29799)
• increased B cell proliferation (MGI Ref ID J:29799)
  • faster proliferation as measured by BrdU incorporation
• increased T cell proliferation (MGI Ref ID J:29799)
  • by 10 days of age, T cells in lymph nodes express high levels of activation markers and are proliferating at an increased rate
  • CD4 T cells are activated prior to CD8 T cells (10 days vs. 15 days of age)
• increased germinal center B cell number (MGI Ref ID J:29799)
• increased plasma cell number (MGI Ref ID J:29799)
  • seen in the spleen by 15 days of age
• abnormal reticulocyte morphology (MGI Ref ID J:29799)
  • marked reduction concurrent with T cell invasion of marrow
• abnormal spleen morphology (MGI Ref ID J:29799)
• increased spleen red pulp amount (MGI Ref ID J:29799)
• spleen hyperplasia (MGI Ref ID J:29799)
  • 15 day old mice exhibit hyperplasia of the white pulp
• decreased hematocrit (MGI Ref ID J:29799)
• increased mean corpuscular hemoglobin (MGI Ref ID J:29799)
  • about twice normal levels, this indicates a hyperchromic anemia
• increased susceptibility to autoimmune hemolytic anemia (MGI Ref ID J:29799)
  • cause of death for mice on this genetic background, as opposed to death caused by inflammatory bowel disease for homozygous mice on a B6.129P2 genetic background
• low mean erythrocyte cell number (MGI Ref ID J:29799)
• homeostasis/metabolism phenotype
• increased circulating bilirubin level (MGI Ref ID J:29799)
• cardiovascular system phenotype
• heart inflammation (MGI Ref ID J:29799)
  • moderate to severe inflammation noted upon necropsy
• vasculitis (MGI Ref ID J:29799)
  • moderate to severe inflammation noted in the major thoracic blood vessels upon necropsy
• digestive/alimentary phenotype
• pancreas inflammation (MGI Ref ID J:29799)
  • moderate to severe inflammation noted upon necropsy
• endocrine/exocrine gland phenotype
• pancreas inflammation (MGI Ref ID J:29799)
  • moderate to severe inflammation noted upon necropsy
• liver/biliary system phenotype
• liver inflammation (MGI Ref ID J:29799)
• respiratory system phenotype
• lung inflammation (MGI Ref ID J:29799)
  • moderate to severe inflammation noted upon necropsy

Il2^tm1Hor/Il2^tm1Hor

        B6.129P2-Il2^tm1Hor

• immune system phenotype
• *normal* immune system phenotype (MGI Ref ID J:125748)
  • bone marrow chimeras (mutant bone marrow in Rag2-deficient hosts) do not develop a wasting autoimmune disease compared to the lethal disease that develops with Il2ra^tm1Dw bone marrow chimeras
• increased T cell number (MGI Ref ID J:125748)
• increased CD4-positive T cell number (MGI Ref ID J:28924)
  • activated T cell numbers fail to decrease to normal levels after immunization with staphylococcal enterotoxin, indicating a problem with peripheral deletion
• increased CD8-positive T cell number (MGI Ref ID J:28924)
  • activated T cell numbers decrease with slower kinetics than wild-type mice after after immunization with staphylococcal enterotoxin
• increased activated T cell number (MGI Ref ID J:28924)
  • higher numbers due to less sensitivity to Fas-mediated cell death (apoptosis)
• increased T cell proliferation (MGI Ref ID J:28924)
  • T cells continue to respond to antigen instead of going into anergy during secondary stimulation with antigens
• hematopoietic system phenotype
• increased T cell number (MGI Ref ID J:125748)
• increased CD4-positive T cell number (MGI Ref ID J:28924)
  • activated T cell numbers fail to decrease to normal levels after immunization with staphylococcal enterotoxin, indicating a problem with peripheral deletion
• increased CD8-positive T cell number (MGI Ref ID J:28924)
  • activated T cell numbers decrease with slower kinetics than wild-type mice after after immunization with staphylococcal enterotoxin
• increased activated T cell number (MGI Ref ID J:28924)
  • higher numbers due to less sensitivity to Fas-mediated cell death (apoptosis)
• increased T cell proliferation (MGI Ref ID J:28924)
  • T cells continue to respond to antigen instead of going into anergy during secondary stimulation with antigens

Il2^tm1Hor/Il2^tm1Hor

        B6.129P2-Il2^tm1Hor/J

• immune system phenotype
• abnormal response to transplant (MGI Ref ID J:113547)
  • wild-type regulatory T cells fail to engraft when adoptively transferred into these mice
• decreased regulatory T cell number (MGI Ref ID J:113547)
  • there is a 2 to 5 fold reduction in the percentage of CD25-postive CD4 T cells in both the thymus and lymph nodes
• enlarged lymph nodes (MGI Ref ID J:113547)
  • increased cellularity of lymph nodes compared to wild-type mice, but lower than what is observed in Il2rb^tm1Mak mice
• increased susceptibility to autoimmune disorder (MGI Ref ID J:113547)
  • generalized symptoms of autoimmunity noted at 4 weeks of age
  • transfer of wild-type regulatory T cells did not prevent autoimmune disorder
• hematopoietic system phenotype
• decreased regulatory T cell number (MGI Ref ID J:113547)
  • there is a 2 to 5 fold reduction in the percentage of CD25-postive CD4 T cells in both the thymus and lymph nodes

Il2^tm1Hor/Il2^tm1Hor

        involves: 129P2/OlaHsd

• reproductive system phenotype
• *normal* reproductive system phenotype (MGI Ref ID J:134589)
  • there are no abnormalities of the placenta, the mesometrial triangle, and differentiation of granulated metrial gland cells (aka uterine NK cells) in the uteri of pregnant mice at day 14 of gestation

View Research Applications

Research Applications

This mouse can be used to support research in many areas including:

Immunology and Inflammation Research
Inflammation (Inflammatory bowel disease)

Il2^tm1Hor related

Cancer Research
Growth Factors/Receptors/Cytokines

Hematological Research
Anemia, Iron Deficiency and Transport Defects (hemolytic)
Immunological Defects

Immunology and Inflammation Research
Autoimmunity (hemolytic anemia)
Growth Factors/Receptors/Cytokines

Genes & Alleles

Gene & Allele Information

Allele Symbol		Il2tm1Hor
Allele Name		targeted mutation 1, Ivan Horak
Allele Type		Targeted (knock-out)
Common Name(s)		IL-2 KO; IL-2-; IL-2null; Il2-;
Mutation Made By		Ivan Horak,   Forschungs institut fur Molekulare
Strain of Origin		129P2/OlaHsd
ES Cell Line Name		E14
ES Cell Line Strain		129P2/OlaHsd
Gene Symbol and Name		Il2, interleukin 2
Chromosome		3
Gene Common Name(s)		IL-2; Il-2; TCGF; lymphokine;
Molecular Note		Insertion of a neomycin-resistance gene into the third exon introduced several stop codons in all reading frames. [MGI Ref ID J:39989]

Genotyping

Genotyping Information

Genotyping Protocols

Il2^tm1Hor, STD PCR, vers. 1

Helpful Links

Optimizing PCR Protocols

References

References

Selected Reference(s)

Schorle H; Holtschke T; Hunig T; Schimpl A; Horak I. 1991. Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting. Nature 352(6336):621-4. [PubMed: 1830926]  [MGI Ref ID J:39989]

Additional References

Antony PA; Paulos CM; Ahmadzadeh M; Akpinarli A; Palmer DC; Sato N; Kaiser A; Hinrichs CS; Klebanoff CA; Tagaya Y; Restifo NP. 2006. Interleukin-2-dependent mechanisms of tolerance and immunity in vivo. J Immunol 176(9):5255-66. [PubMed: 16621991]  [MGI Ref ID J:115150]

Horak I. 1995. Immunodeficiency in IL-2-knockout mice. Clin Immunol Immunopathol 76(3 Pt 2):S172-3. [PubMed: 7554463]  [MGI Ref ID J:28804]

Kundig TM; Schorle H; Bachmann MF; Hengartner H; Zinkernagel RM; Horak I. 1993. Immune responses in interleukin-2-deficient mice. Science 262(5136):1059-61. [PubMed: 8235625]  [MGI Ref ID J:15573]

Sadlack B; Lohler J; Schorle H; Klebb G; Haber H; Sickel E; Noelle RJ; Horak I. 1995. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol 25(11):3053-9. [PubMed: 7489743]  [MGI Ref ID J:29799]

Sadlack B; Merz H; Schorle H; Schimpl A; Feller AC; Horak I. 1993. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene [see comments] Cell 75(2):253-61. [PubMed: 8402910]  [MGI Ref ID J:15223]

Il2^tm1Hor related

Almeida AR; Legrand N; Papiernik M; Freitas AA. 2002. Homeostasis of peripheral CD4+ T cells: IL-2R alpha and IL-2 shape a population of regulatory cells that controls CD4+ T cell numbers. J Immunol 169(9):4850-60. [PubMed: 12391195]  [MGI Ref ID J:125748]

Antony PA; Paulos CM; Ahmadzadeh M; Akpinarli A; Palmer DC; Sato N; Kaiser A; Hinrichs CS; Klebanoff CA; Tagaya Y; Restifo NP. 2006. Interleukin-2-dependent mechanisms of tolerance and immunity in vivo. J Immunol 176(9):5255-66. [PubMed: 16621991]  [MGI Ref ID J:115150]

Antony PA; Piccirillo CA; Akpinarli A; Finkelstein SE; Speiss PJ; Surman DR; Palmer DC; Chan CC; Klebanoff CA; Overwijk WW; Rosenberg SA; Restifo NP. 2005. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 174(5):2591-601. [PubMed: 15728465]  [MGI Ref ID J:129825]

Antov A; Yang L; Vig M; Baltimore D; Van Parijs L. 2003. Essential role for STAT5 signaling in CD25+CD4+ regulatory T cell homeostasis and the maintenance of self-tolerance. J Immunol 171(7):3435-41. [PubMed: 14500638]  [MGI Ref ID J:85631]

Ashcroft AJ; Cruickshank SM; Croucher PI; Perry MJ; Rollinson S; Lippitt JM; Child JA; Dunstan C; Felsburg PJ; Morgan GJ; Carding SR. 2003. Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity 19(6):849-61. [PubMed: 14670302]  [MGI Ref ID J:86997]

Bachmann MF; Schorle H; Kuhn R; Muller W; Hengartner H; Zinkernagel RM; Horak I. 1995. Antiviral immune responses in mice deficient for both interleukin-2 and interleukin-4. J Virol 69(8):4842-6. [PubMed: 7609051]  [MGI Ref ID J:26861]

Barmeyer C; Harren M; Schmitz H; Heinzel-Pleines U; Mankertz J; Seidler U; Horak I; Wiedenmann B; Fromm M; Schulzke JD. 2004. Mechanisms of diarrhea in the interleukin-2-deficient mouse model of colonic inflammation. Am J Physiol Gastrointest Liver Physiol 286(2):G244-52. [PubMed: 14715519]  [MGI Ref ID J:87603]

Barmeyer C; Horak I; Zeitz M; Fromm M; Schulzke JD. 2002. The interleukin-2-deficient mouse model Pathobiology 70(3):139-42. [PubMed: 12571417]  [MGI Ref ID J:82223]

Bassiri H; Carding SR. 2001. A requirement for IL-2/IL-2 receptor signaling in intrathymic negative selection. J Immunol 166(10):5945-54. [PubMed: 11342609]  [MGI Ref ID J:110891]

Batchelder JM; Burns JM Jr; Cigel FK; Lieberg H; Manning DD; Pepper BJ; Yanez DM; van der Heyde H; Weidanz WP. 2003. Plasmodium chabaudi adami: interferon-gamma but not IL-2 is essential for the expression of cell-mediated immunity against blood-stage parasites in mice. Exp Parasitol 105(2):159-66. [PubMed: 14969693]  [MGI Ref ID J:102606]

Beck RD Jr; King MA; Ha GK; Cushman JD; Huang Z; Petitto JM. 2005. IL-2 deficiency results in altered septal and hippocampal cytoarchitecture: relation to development and neurotrophins. J Neuroimmunol 160(1-2):146-53. [PubMed: 15710467]  [MGI Ref ID J:101962]

Beck RD Jr; Wasserfall C; Ha GK; Cushman JD; Huang Z; Atkinson MA; Petitto JM. 2005. Changes in hippocampal IL-15, related cytokines, and neurogenesis in IL-2 deficient mice. Brain Res 1041(2):223-230. [PubMed: 15829231]  [MGI Ref ID J:97426]

Beck RD; King MA; Huang Z; Petitto JM. 2002. Alterations in septohippocampal cholinergic neurons resulting from interleukin-2 gene knockout. Brain Res 955(1-2):16-23. [PubMed: 12419517]  [MGI Ref ID J:80486]

Behrens GM; Li M; Davey GM; Allison J; Flavell RA; Carbone FR; Heath WR. 2004. Helper requirements for generation of effector CTL to islet beta cell antigens. J Immunol 172(9):5420-6. [PubMed: 15100283]  [MGI Ref ID J:89639]

Bemiss CJ; Mahon BD; Henry A; Weaver V; Cantorna MT. 2002. Interleukin-2 is one of the targets of 1,25-dihydroxyvitamin D3 in the immune system. Arch Biochem Biophys 402(2):249-54. [PubMed: 12051670]  [MGI Ref ID J:114521]

Beyersdorf N; Ding X; Tietze JK; Hanke T. 2007. Characterization of mouse CD4 T cell subsets defined by expression of KLRG1. Eur J Immunol 37(12):3445-54. [PubMed: 18034419]  [MGI Ref ID J:128529]

Brinster C; Shevach EM. 2005. Bone marrow-derived dendritic cells reverse the anergic state of CD4+CD25+ T cells without reversing their suppressive function. J Immunol 175(11):7332-40. [PubMed: 16301639]  [MGI Ref ID J:122138]

Buhlmann JE; Gonzalez M; Ginther B; Panoskaltsis-Mortari A; Blazar BR; Greiner DL; Rossini AA; Flavell R; Noelle RJ. 1999. Cutting edge: sustained expansion of CD8+ T cells requires CD154 expression by Th cells in acute graft versus host disease. J Immunol 162(8):4373-6. [PubMed: 10201970]  [MGI Ref ID J:119788]

Burchill MA; Yang J; Vogtenhuber C; Blazar BR; Farrar MA. 2007. IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J Immunol 178(1):280-90. [PubMed: 17182565]  [MGI Ref ID J:141932]

Carrier Y; Yuan J; Kuchroo VK; Weiner HL. 2007. Th3 cells in peripheral tolerance. II. TGF-beta-transgenic Th3 cells rescue IL-2-deficient mice from autoimmunity. J Immunol 178(1):172-8. [PubMed: 17182552]  [MGI Ref ID J:141942]

Chastagner P; Reddy J; Theze J. 2002. Lymphoadenopathy in IL-2-Deficient Mice: Further Characterization and Overexpression of the Antiapoptotic Molecule Cellular FLIP. J Immunol 169(7):3644-51. [PubMed: 12244156]  [MGI Ref ID J:79241]

Chen J; Astle CM; Harrison DE. 2002. Hematopoietic stem cell functional failure in interleukin-2-deficient mice. J Hematother Stem Cell Res 11(6):905-12. [PubMed: 12590705]  [MGI Ref ID J:115513]

Cho JH; Boyman O; Kim HO; Hahm B; Rubinstein MP; Ramsey C; Kim DM; Surh CD; Sprent J. 2007. An intense form of homeostatic proliferation of naive CD8+ cells driven by IL-2. J Exp Med 204(8):1787-801. [PubMed: 17664294]  [MGI Ref ID J:125917]

Contractor NV; Bassiri H; Reya T; Park AY; Baumgart DC; Wasik MA; Emerson SG; Carding SR. 1998. Lymphoid hyperplasia, autoimmunity, and compromised intestinal intraepithelial lymphocyte development in colitis-free gnotobiotic IL-2-deficient mice. J Immunol 160(1):385-94. [PubMed: 9551995]  [MGI Ref ID J:46312]

D'Cruz LM; Klein L. 2005. Development and function of agonist-induced CD25+Foxp3+ regulatory T cells in the absence of interleukin 2 signaling. Nat Immunol 6(11):1152-9. [PubMed: 16227983]  [MGI Ref ID J:112603]

D'Souza WN; Lefrancois L. 2003. IL-2 is not required for the initiation of CD8 T cell cycling but sustains expansion. J Immunol 171(11):5727-35. [PubMed: 14634080]  [MGI Ref ID J:117985]

Dai Z; Konieczny BT; Baddoura FK; Lakkis FG. 1998. Impaired alloantigen-mediated T cell apoptosis and failure to induce long-term allograft survival in IL-2-deficient mice. J Immunol 161(4):1659-63. [PubMed: 9712028]  [MGI Ref ID J:118720]

Dai Z; Konieczny BT; Lakkis FG. 2000. The dual role of IL-2 in the generation and maintenance of CD8+ memory T cells J Immunol 165(6):3031-6. [PubMed: 10975812]  [MGI Ref ID J:64553]

Demaison C; Fiette L; Blanchetiere V; Schimpl A; Theze J; Froussard P. 1998. IL-2 receptor alpha-chain expression is independently regulated in primary and secondary lymphoid organs. J Immunol 161(4):1977-82. [PubMed: 9712069]  [MGI Ref ID J:110999]

Diaz-de-Durana Y; Mantchev GT; Bram RJ; Franco A. 2006. TACI-BLyS signaling via B-cell-dendritic cell cooperation is required for naive CD8+ T-cell priming in vivo. Blood 107(2):594-601. [PubMed: 16195331]  [MGI Ref ID J:126637]

Dooms H; Kahn E; Knoechel B; Abbas AK. 2004. IL-2 induces a competitive survival advantage in T lymphocytes. J Immunol 172(10):5973-9. [PubMed: 15128779]  [MGI Ref ID J:89699]

Dooms H; Wolslegel K; Lin P; Abbas AK. 2007. Interleukin-2 enhances CD4+ T cell memory by promoting the generation of IL-7R alpha-expressing cells. J Exp Med 204(3):547-57. [PubMed: 17312008]  [MGI Ref ID J:125364]

Duffy D; Yang CP; Heath A; Garside P; Bell EB. 2006. Naive T-cell receptor transgenic T cells help memory B cells produce antibody. Immunology 119(3):376-84. [PubMed: 17067314]  [MGI Ref ID J:118532]

Ehrhardt RO; Ludviksson BR; Gray B; Neurath M; Strober W. 1997. Induction and prevention of colonic inflammation in IL-2-deficient mice. J Immunol 158(2):566-73. [PubMed: 8992969]  [MGI Ref ID J:110763]

Elias KM; Laurence A; Davidson TS; Stephens G; Kanno Y; Shevach EM; O'Shea JJ. 2008. Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway. Blood 111(3):1013-20. [PubMed: 17951529]  [MGI Ref ID J:130685]

Enomoto T; Weghorst CM; Ward JM; Anderson LM; Perantoni AO; Rice JM. 1993. Low frequency of H-ras activation in naturally occurring hepatocellular tumors of C3H/HeNCr mice. Carcinogenesis 14(9):1939-44. [PubMed: 8403222]  [MGI Ref ID J:14839]

Fehervari Z; Sakaguchi S. 2004. Control of Foxp3+ CD25+CD4+ regulatory cell activation and function by dendritic cells. Int Immunol 16(12):1769-80. [PubMed: 15520045]  [MGI Ref ID J:94004]

Fontenot JD; Rasmussen JP; Gavin MA; Rudensky AY. 2005. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 6(11):1142-51. [PubMed: 16227984]  [MGI Ref ID J:112602]

French AR; Sjolin H; Kim S; Koka R; Yang L; Young DA; Cerboni C; Tomasello E; Ma A; Vivier E; Karre K; Yokoyama WM. 2006. DAP12 signaling directly augments proproliferative cytokine stimulation of NK cells during viral infections. J Immunol 177(8):4981-90. [PubMed: 17015680]  [MGI Ref ID J:139300]

Freyschmidt-Paul P; McElwee KJ; Hoffmann R; Sundberg JP; Kissling S; Hummel S; Vitacolonna M; Kopp-Schneider A; Zoller M. 2005. Reduced expression of interleukin-2 decreases the frequency of alopecia areata onset in C3H/HeJ mice. J Invest Dermatol 125(5):945-51. [PubMed: 16297194]  [MGI Ref ID J:102954]

Gaetke LM; Oz HS; de Villiers WJ; Varilek GW; Frederich RC. 2002. The leptin defense against wasting is abolished in the IL-2-deficient mouse model of inflammatory bowel disease. J Nutr 132(5):893-6. [PubMed: 11983809]  [MGI Ref ID J:76491]

Grassl G; Pummerer CL; Horak I; Neu N. 1997. Induction of autoimmune myocarditis in interleukin-2-deficient mice. Circulation 95(7):1773-6. [PubMed: 9107162]  [MGI Ref ID J:40082]

Guimond MJ; Luross JA; Wang B; Terhorst C; Danial S; Croy BA. 1997. Absence of natural killer cells during murine pregnancy is associated with reproductive compromise in TgE26 mice. Biol Reprod 56(1):169-79. [PubMed: 9002646]  [MGI Ref ID J:134589]

Hancock WW; Tsai TL; Madaio MP; Gasser DL. 2003. Cutting Edge: Multiple autoimmune pathways in kd/kd mice. J Immunol 171(6):2778-81. [PubMed: 12960297]  [MGI Ref ID J:85380]

Herblot S; Chastagner P; Samady L; Moreau JL; Demaison C; Froussard P; Liu X; Bonnet J; Theze J. 1999. IL-2-dependent expression of genes involved in cytoskeleton organization, oncogene regulation, and transcriptional control. J Immunol 162(6):3280-8. [PubMed: 10092780]  [MGI Ref ID J:53462]

Herold KC; Lu J; Rulifson I; Vezys V; Taub D; Grusby MJ; Bluestone JA. 1997. Regulation of C-C chemokine production by murine T cells by CD28/B7 costimulation. J Immunol 159(9):4150-3. [PubMed: 9379007]  [MGI Ref ID J:110673]

Hofstetter HH; Sewell DL; Liu F; Sandor M; Forsthuber T; Lehmann PV; Fabry Z. 2003. Autoreactive T cells promote post-traumatic healing in the central nervous system. J Neuroimmunol 134(1-2):25-34. [PubMed: 12507769]  [MGI Ref ID J:119263]

Horak I; Lohler J; Ma A; Smith KA. 1995. Interleukin-2 deficient mice: a new model to study autoimmunity and self-tolerance. Immunol Rev 148:35-44. [PubMed: 8825281]  [MGI Ref ID J:40087]

Huang H; Hao S; Li F; Ye Z; Yang J; Xiang J. 2007. CD4+ Th1 cells promote CD8+ Tc1 cell survival, memory response, tumor localization and therapy by targeted delivery of interleukin 2 via acquired pMHC I complexes. Immunology 120(2):148-59. [PubMed: 17274112]  [MGI Ref ID J:122309]

Hwang KW; Sweatt WB; Mashayekhi M; Palucki DA; Sattar H; Chuang E; Alegre ML. 2004. Transgenic expression of CTLA-4 controls lymphoproliferation in IL-2-deficient mice. J Immunol 173(9):5415-24. [PubMed: 15494488]  [MGI Ref ID J:93742]

Klebanoff CA; Finkelstein SE; Surman DR; Lichtman MK; Gattinoni L; Theoret MR; Grewal N; Spiess PJ; Antony PA; Palmer DC; Tagaya Y; Rosenberg SA; Waldmann TA; Restifo NP. 2004. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc Natl Acad Sci U S A 101(7):1969-74. [PubMed: 14762166]  [MGI Ref ID J:90388]

Kneitz B; Herrmann T; Yonehara S; Schimpl A. 1995. Normal clonal expansion but impaired Fas-mediated cell death and anergy induction in interleukin-2-deficient mice. Eur J Immunol 25(9):2572-7. [PubMed: 7589128]  [MGI Ref ID J:28924]

Kretschmer K; Apostolou I; Hawiger D; Khazaie K; Nussenzweig MC; von Boehmer H. 2005. Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol 6(12):1219-27. [PubMed: 16244650]  [MGI Ref ID J:112677]

Kundig TM; Schorle H; Bachmann MF; Hengartner H; Zinkernagel RM; Horak I. 1993. Immune responses in interleukin-2-deficient mice. Science 262(5136):1059-61. [PubMed: 8235625]  [MGI Ref ID J:15573]

Kung JT; Beller D; Ju ST. 1998. Lymphokine regulation of activation-induced apoptosis in T cells of IL-2 and IL-2R beta knockout mice. Cell Immunol 185(2):158-63. [PubMed: 9636694]  [MGI Ref ID J:114259]

Laurence A; Tato CM; Davidson TS; Kanno Y; Chen Z; Yao Z; Blank RB; Meylan F; Siegel R; Hennighausen L; Shevach EM; O'shea JJ. 2007. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26(3):371-81. [PubMed: 17363300]  [MGI Ref ID J:120176]

Li XC; Roy-Chaudhury P; Hancock WW; Manfro R; Zand MS; Li Y; Zheng XX; Nickerson PW; Steiger J; Malek TR; Strom TB. 1998. IL-2 and IL-4 double knockout mice reject islet allografts: a role for novel T cell growth factors in allograft rejection. J Immunol 161(2):890-6. [PubMed: 9670967]  [MGI Ref ID J:48547]

Liston A; Siggs OM; Goodnow CC. 2007. Tracing the action of IL-2 in tolerance to islet-specific antigen. Immunol Cell Biol 85(4):338-42. [PubMed: 17372610]  [MGI Ref ID J:141735]

Liu Y; Zhang P; Li J; Kulkarni AB; Perruche S; Chen W. 2008. A critical function for TGF-beta signaling in the development of natural CD4+CD25+Foxp3+ regulatory T cells. Nat Immunol 9(6):632-40. [PubMed: 18438410]  [MGI Ref ID J:136291]

Lohr J; Knoechel B; Wang JJ; Villarino AV; Abbas AK. 2006. Role of IL-17 and regulatory T lymphocytes in a systemic autoimmune disease. J Exp Med 203(13):2785-91. [PubMed: 17130300]  [MGI Ref ID J:124600]

Ludviksson BR; Ehrhardt RO; Strober W. 1997. TGF-beta production regulates the development of the 2,4,6-trinitrophenol-conjugated keyhole limpet hemocyanin-induced colonic inflammation in IL-2-deficient mice. J Immunol 159(7):3622-8. [PubMed: 9317162]  [MGI Ref ID J:110678]

Ludviksson BR; Gray B; Strober W; Ehrhardt RO. 1997. Dysregulated intrathymic development in the IL-2-deficient mouse leads to colitis-inducing thymocytes. J Immunol 158(1):104-11. [PubMed: 8977180]  [MGI Ref ID J:37220]

Ma A; Datta M; Margosian E; Chen J; Horak I. 1995. T cells, but not B cells, are required for bowel inflammation in interleukin 2-deficient mice. J Exp Med 182(5):1567-72. [PubMed: 7595226]  [MGI Ref ID J:29999]

Malek TR; Yu A; Vincek V; Scibelli P; Kong L. 2002. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity 17(2):167-78. [PubMed: 12196288]  [MGI Ref ID J:113547]

Massberg S; Brand K; Gruner S; Page S; Muller E; Muller I; Bergmeier W; Richter T; Lorenz M; Konrad I; Nieswandt B; Gawaz M. 2002. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 196(7):887-96. [PubMed: 12370251]  [MGI Ref ID J:112015]

Meijssen MA; Brandwein SL; Reinecker HC; Bhan AK; Podolsky DK. 1998. Alteration of gene expression by intestinal epithelial cells precedes colitis in interleukin-2-deficient mice. Am J Physiol 274(3 Pt 1):G472-9. [PubMed: 9530147]  [MGI Ref ID J:46723]

Muller M; Fink K; Geisel J; Kahl F; Jilge B; Reimann J; Mach N; Autenrieth IB; Frick JS. 2008. Intestinal colonization of IL-2 deficient mice with non-colitogenic B. vulgatus prevents DC maturation and T-cell polarization. PLoS ONE 3(6):e2376. [PubMed: 18545662]  [MGI Ref ID J:137149]

Nagahama K; Ogawa A; Shirane K; Shimomura Y; Sugimoto K; Mizoguchi A. 2008. Protein kinase C theta plays a fundamental role in different types of chronic colitis. Gastroenterology 134(2):459-69. [PubMed: 18155708]  [MGI Ref ID J:135589]

Nelson BH. 2004. IL-2, regulatory T cells, and tolerance. J Immunol 172(7):3983-8. [PubMed: 15034008]  [MGI Ref ID J:88679]

Papiernik M; de Moraes ML; Pontoux C; Vasseur F; Penit C. 1998. Regulatory CD4 T cells: expression of IL-2R alpha chain, resistance to clonal deletion and IL-2 dependency. Int Immunol 10(4):371-8. [PubMed: 9620592]  [MGI Ref ID J:110541]

Petitto JM; Huang Z; Lo J; Streit WJ. 2003. IL-2 gene knockout affects T lymphocyte trafficking and the microglial response to regenerating facial motor neurons. J Neuroimmunol 134(1-2):95-103. [PubMed: 12507776]  [MGI Ref ID J:105891]

Petitto JM; McNamara RK; Gendreau PL; Huang Z; Jackson AJ. 1999. Impaired learning and memory and altered hippocampal neurodevelopment resulting from interleukin-2 gene deletion. J Neurosci Res 56(4):441-6. [PubMed: 10340751]  [MGI Ref ID J:78385]

Petitto JM; Streit WJ; Huang Z; Butfiloski E; Schiffenbauer J. 2000. Interleukin-2 gene deletion produces a robust reduction in susceptibility to experimental autoimmune encephalomyelitis in C57BL/6 mice. Neurosci Lett 285(1):66-70. [PubMed: 10788709]  [MGI Ref ID J:62455]

Porter BO; Malek TR. 1999. IL-2Rbeta/IL-7Ralpha doubly deficient mice recapitulate the thymic and intraepithelial lymphocyte (IEL) developmental defects of gammac-/- mice: roles for both IL-2 and IL-15 in CD8alphaalpha IEL development. J Immunol 163(11):5906-12. [PubMed: 10570276]  [MGI Ref ID J:58655]

Poussier P; Ning T; Chen J; Banerjee D; Julius M. 2000. Intestinal inflammation observed in IL-2R/IL-2 mutant mice is associated with impaired intestinal T lymphopoiesis [see comments] Gastroenterology 118(5):880-91. [PubMed: 10784587]  [MGI Ref ID J:61842]

Powell JD; Bruniquel D; Schwartz RH. 2001. TCR engagement in the absence of cell cycle progression leads to T cell anergy independent of p27(Kip1). Eur J Immunol 31(12):3737-46. [PubMed: 11745394]  [MGI Ref ID J:115423]

Qian BF; El-Salhy M; Melgar S; Hammarstrom ML; Danielsson A. 2000. Neuroendocrine changes in colon of mice with a disrupted IL-2 gene. Clin Exp Immunol 120(3):424-33. [PubMed: 10844519]  [MGI Ref ID J:62304]

Rakoff-Nahoum S; Hao L; Medzhitov R. 2006. Role of toll-like receptors in spontaneous commensal-dependent colitis. Immunity 25(2):319-29. [PubMed: 16879997]  [MGI Ref ID J:113467]

Ramsey C; Rubinstein MP; Kim DM; Cho JH; Sprent J; Surh CD. 2008. The lymphopenic environment of CD132 (common gamma-chain)-deficient hosts elicits rapid homeostatic proliferation of naive T cells via IL-15. J Immunol 180(8):5320-6. [PubMed: 18390713]  [MGI Ref ID J:134238]

Reddy J; Chastagner P; Fiette L; Liu X; Theze J. 2001. IL-2-induced tumor necrosis factor (TNF)-ss expression: further analysis in the IL-2 knockout model, and comparison with TNF-alpha, lymphotoxin-ss, TNFR1 and TNFR2 modulation. Int Immunol 13(2):135-47. [PubMed: 11157847]  [MGI Ref ID J:67178]

Reya T; Bassiri H; Biancaniello R; Carding SR. 1998. Thymic stromal-cell abnormalities and dysregulated T-cell development in IL-2-deficient mice. Dev Immunol 5(4):287-302. [PubMed: 9814585]  [MGI Ref ID J:113077]

Reya T; Contractor NV; Couzens MS; Wasik MA; Emerson SG; Carding SR. 1998. Abnormal myelocytic cell development in interleukin-2 (IL-2)-deficient mice: evidence for the involvement of IL-2 in myelopoiesis. Blood 91(8):2935-47. [PubMed: 9531604]  [MGI Ref ID J:47458]

Roy-Chaudhury P; Manfro RC; Steiger J; Nickerson PW; Tian Y; Zheng XX; Li YS; Strom TB. 1997. IL-2 and IL-4 double knock-out mice reject islet allografts: a role for novel T-cell growth factors? Transplant Proc 29(1-2):1083-4. [PubMed: 9123210]  [MGI Ref ID J:38784]

Sadlack B; Kuhn R; Schorle H; Rajewsky K; Muller W; Horak I. 1994. Development and proliferation of lymphocytes in mice deficient for both interleukins-2 and -4. Eur J Immunol 24(1):281-4. [PubMed: 7517363]  [MGI Ref ID J:16662]

Sadlack B; Lohler J; Schorle H; Klebb G; Haber H; Sickel E; Noelle RJ; Horak I. 1995. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol 25(11):3053-9. [PubMed: 7489743]  [MGI Ref ID J:29799]

Sadlack B; Merz H; Schorle H; Schimpl A; Feller AC; Horak I. 1993. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene [see comments] Cell 75(2):253-61. [PubMed: 8402910]  [MGI Ref ID J:15223]

Schimpl A; Hunig T; Elbe A; Berberich I; Kramer S; Merz H; Feller AC; Sadlack B; Schorle H; Horak I. 1994. Development and function of the immune system in mice with targeted disruption of the interleukin-2 gene.. In: Transgenesis and Targeted Mutagenesis in Immunology. Academic Press, Inc..  [MGI Ref ID J:21663]

Schultz M; Clarke SH; Arnold LW; Sartor RB; Tonkonogy SL. 2001. Disrupted B-lymphocyte development and survival in interleukin-2-deficient mice. Immunology 104(2):127-34. [PubMed: 11683951]  [MGI Ref ID J:72207]

Schultz M; Tonkonogy SL; Sellon RK; Veltkamp C; Godfrey VL; Kwon J ; Grenther WB ; Balish E ; Horak I ; Sartor RB. 1999. IL-2-deficient mice raised under germfree conditions develop delayed mild focal intestinal inflammation. Am J Physiol 276(6 Pt 1):G1461-72. [PubMed: 10362650]  [MGI Ref ID J:55812]

Schuppler M; Lotzsch K; Waidmann M; Autenrieth IB. 2004. An abundance of Escherichia coli is harbored by the mucosa-associated bacterial flora of interleukin-2-deficient mice. Infect Immun 72(4):1983-90. [PubMed: 15039318]  [MGI Ref ID J:88998]

Seixas E; Fonseca L; Langhorne J. 2002. The influence of gammadelta T cells on the CD4+ T cell and antibody response during a primary Plasmodium chabaudi chabaudi infection in mice. Parasite Immunol 24(3):131-40. [PubMed: 11982858]  [MGI Ref ID J:134387]

Sepulveda H; Cerwenka A; Morgan T; Dutton RW. 1999. CD28, IL-2-independent costimulatory pathways for CD8 T lymphocyte activation. J Immunol 163(3):1133-42. [PubMed: 10415007]  [MGI Ref ID J:118773]

Seril DN; Liao J; Yang CS; Yang GY. 2005. Systemic iron supplementation replenishes iron stores without enhancing colon carcinogenesis in murine models of ulcerative colitis: comparison with iron-enriched diet. Dig Dis Sci 50(4):696-707. [PubMed: 15844705]  [MGI Ref ID J:98648]

Shah SA; Simpson SJ; Brown LF; Comiskey M; de Jong YP; Allen D; Terhorst C. 1998. Development of colonic adenocarcinomas in a mouse model of ulcerative colitis. Inflamm Bowel Dis 4(3):196-202. [PubMed: 9741021]  [MGI Ref ID J:51450]

Sharma R; Zheng L; Guo X; Fu SM; Ju ST; Jarjour WN. 2006. Novel animal models for Sjogren's syndrome: expression and transfer of salivary gland dysfunction from regulatory T cell-deficient mice. J Autoimmun 27(4):289-96. [PubMed: 17207605]  [MGI Ref ID J:125129]

Shibata K; Yamada H; Nakamura R; Sun X; Itsumi M; Yoshikai Y. 2008. Identification of CD25+ gammadelta T cells as fetal thymus-derived naturally occurring IL-17 producers. J Immunol 181(9):5940-7. [PubMed: 18941182]  [MGI Ref ID J:140747]

Shimoda M; Mmanywa F; Joshi SK; Li T; Miyake K; Pihkala J; Abbas JA; Koni PA. 2006. Conditional ablation of MHC-II suggests an indirect role for MHC-II in regulatory CD4 T cell maintenance. J Immunol 176(11):6503-11. [PubMed: 16709807]  [MGI Ref ID J:131774]

Simpson SJ; Mizoguchi E; Allen D; Bhan AK; Terhorst C. 1995. Evidence that CD4+, but not CD8+ T cells are responsible for murine interleukin-2-deficient colitis. Eur J Immunol 25(9):2618-25. [PubMed: 7589135]  [MGI Ref ID J:39981]

Sohn KJ; Shah SA; Reid S; Choi M; Carrier J; Comiskey M; Terhorst C; Kim YI. 2001. Molecular Genetics of Ulcerative Colitis-associated Colon Cancer in the Interleukin 2- and beta(2)-Microglobulin-deficient Mouse. Cancer Res 61(18):6912-7. [PubMed: 11559569]  [MGI Ref ID J:71656]

Spierings DC; Lemmens EE; Grewal K; Schoenberger SP; Green DR. 2006. Duration of CTL activation regulates IL-2 production required for autonomous clonal expansion. Eur J Immunol 36(7):1707-17. [PubMed: 16791878]  [MGI Ref ID J:115790]

Steiger J; Nickerson PW; Steurer W; Moscovitch-Lopatin M; Strom TB. 1995. IL-2 knockout recipient mice reject islet cell allografts. J Immunol 155(1):489-98. [PubMed: 7602120]  [MGI Ref ID J:26198]

Su HC; Cousens LP; Fast LD; Slifka MK; Bungiro RD; Ahmed R; Biron CA. 1998. CD4+ and CD8+ T cell interactions in IFN-gamma and IL-4 responses to viral infections: requirements for IL-2. J Immunol 160(10):5007-17. [PubMed: 9590250]  [MGI Ref ID J:111005]

Sund M; Xu LL; Rahman A; Qian BF; Hammarstrom ML; Danielsson A. 2005. Reduced susceptibility to dextran sulphate sodium-induced colitis in the interleukin-2 heterozygous (IL-2) mouse. Immunology 114(4):554-64. [PubMed: 15804292]  [MGI Ref ID J:97439]

Tai X; Cowan M; Feigenbaum L; Singer A. 2005. CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nat Immunol 6(2):152-62. [PubMed: 15640801]  [MGI Ref ID J:95668]

Vang KB; Yang J; Mahmud SA; Burchill MA; Vegoe AL; Farrar MA. 2008. IL-2, -7, and -15, but not thymic stromal lymphopoeitin, redundantly govern CD4+Foxp3+ regulatory T cell development. J Immunol 181(5):3285-90. [PubMed: 18714000]  [MGI Ref ID J:138950]

Vosshenrich CA; Lesjean-Pottier S; Hasan M; Richard-Le Goff O; Corcuff E; Mandelboim O; Di Santo JP. 2007. CD11cloB220+ interferon-producing killer dendritic cells are activated natural killer cells. J Exp Med 204(11):2569-78. [PubMed: 17923507]  [MGI Ref ID J:126100]

Vosshenrich CA; Ranson T; Samson SI; Corcuff E; Colucci F; Rosmaraki EE; Di Santo JP. 2005. Roles for common cytokine receptor gamma-chain-dependent cytokines in the generation, differentiation, and maturation of NK cell precursors and peripheral NK cells in vivo. J Immunol 174(3):1213-21. [PubMed: 15661875]  [MGI Ref ID J:96422]

Waidmann M; Bechtold O; Frick JS; Lehr HA; Schubert S; Dobrindt U; Loeffler J; Bohn E; Autenrieth IB. 2003. Bacteroides vulgatus protects against Escherichia coli-induced colitis in gnotobiotic interleukin-2-deficient mice. Gastroenterology 125(1):162-77. [PubMed: 12851881]  [MGI Ref ID J:84099]

Williams MA; Tyznik AJ; Bevan MJ. 2006. Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells. Nature 441(7095):890-3. [PubMed: 16778891]  [MGI Ref ID J:110049]

Wilson EB; Livingstone AM. 2008. Cutting edge: CD4+ T cell-derived IL-2 is essential for help-dependent primary CD8+ T cell responses. J Immunol 181(11):7445-8. [PubMed: 19017930]  [MGI Ref ID J:142211]

Wolf M; Schimpl A; Hunig T. 2001. Control of T cell hyperactivation in IL-2-deficient mice by CD4(+)CD25(-) and CD4(+)CD25(+) T cells: evidence for two distinct regulatory mechanisms. Eur J Immunol 31(6):1637-45. [PubMed: 11385607]  [MGI Ref ID J:88349]

Wong P; Pamer EG. 2004. Disparate in vitro and in vivo requirements for IL-2 during antigen-independent CD8 T cell expansion. J Immunol 172(4):2171-6. [PubMed: 14764683]  [MGI Ref ID J:87997]

Wrenshall LE; Stevens ET; Smith DR; Miller JD. 2007. Maternal microchimerism leads to the presence of interleukin-2 in interleukin-2 knock out mice: implications for the role of interleukin-2 in thymic function. Cell Immunol 245(2):80-90. [PubMed: 17524378]  [MGI Ref ID J:123478]

Wu HJ; Sawaya H; Binstadt B; Brickelmaier M; Blasius A; Gorelik L; Mahmood U; Weissleder R; Carulli J; Benoist C; Mathis D. 2007. Inflammatory arthritis can be reined in by CpG-induced DC-NK cell cross talk. J Exp Med 204(8):1911-22. [PubMed: 17646407]  [MGI Ref ID J:125952]

Xiao S; Sung SS; Fu SM; Ju ST. 2003. Combining Fas mutation with interleukin-2 deficiency prevents Colitis and Lupus: implicating interleukin-2 for auto-reactive T cell expansion and Fas ligand for colon epithelial cell death. J Biol Chem 278(52):52730-8. [PubMed: 14525977]  [MGI Ref ID J:87085]

Yamanouchi J; Rainbow D; Serra P; Howlett S; Hunter K; Garner VE; Gonzalez-Munoz A; Clark J; Veijola R; Cubbon R; Chen SL; Rosa R; Cumiskey AM; Serreze DV; Gregory S; Rogers J; Lyons PA; Healy B; Smink LJ; Todd JA; Peterson LB; Wicker LS; Santamaria P. 2007. Interleukin-2 gene variation impairs regulatory T cell function and causes autoimmunity. Nat Genet 39(3):329-37. [PubMed: 17277778]  [MGI Ref ID J:120349]

Yang F; de Villiers WJ; Lee EY; McClain CJ; Varilek GW. 1999. Increased nuclear factor-kappaB activation in colitis of interleukin-2-deficient mice. J Lab Clin Med 134(4):378-85. [PubMed: 10521084]  [MGI Ref ID J:57978]

Zand MS; Li Y; Hancock W; Li XC; Roy-Chaudhury P; Zheng XX; Strom TB. 2000. Interleukin-2 and interferon-gamma double knockout mice reject heterotopic cardiac allografts Transplantation 70(9):1378-81. [PubMed: 11087156]  [MGI Ref ID J:65781]

Zheng L; Sharma R; Kung JT; Deshmukh US; Jarjour WN; Fu SM; Ju ST. 2008. Pervasive and stochastic changes in the TCR repertoire of regulatory T-cell-deficient mice. Int Immunol 20(4):517-23. [PubMed: 18310063]  [MGI Ref ID J:133521]

de Villiers WJ; Varilek GW; de Beer FC; Guo JT; Kindy MS. 2000. Increased serum amyloid a levels reflect colitis severity and precede amyloid formation in IL-2 knockout mice. Cytokine 12(9):1337-47. [PubMed: 10975993]  [MGI Ref ID J:102643]

Health & husbandry

Health & Colony Maintenance Information

Colony Maintenance

Diet Information	LabDiet® 5K52/5K67

Purchasing information

Pricing, Supply Level & Notes, Controls, General Terms & Conditions

Pricing

Supply Details

Standard Supply

Cryopreserved. Ready for recovery. Please refer to pricing and supply notes for further information.

Supply Notes

Cryorecovery - Standard. At least two mice that carry the mutation (if it is a mutant strain) will be provided. The total number of animals provided, their gender and genotype will vary. Please inquire if larger numbers of animals with specific genotypes and genders are needed. IMPORTANT NOTE: The genotypes of the animals provided may not reflect the mating scheme utilized by The Jackson Laboratory prior to cryopreservation, or that discussed in the strain description. Please inquire for possible genotypes for this specific strain. Animals typically ship within 13 to 16 weeks from your order. If a second cryorecovery is needed in order to provide the minimum number of animals, animals will typically ship within 25 weeks. Cryorecovery to establish a Dedicated Supply for greater quantities of mice. One to two pairs will be recovered to establish a Dedicated Supply of mice. Price by quotation. For more information on Dedicated Supply, please contact JAX® Services, Tel: 1-800-422-6423 or 1-207-288-5845. This strain is included in the Induced Mutant Resource Colony collection. Genomic DNA is available for this strain from the Mouse DNA Resource.

Control Information

	Control
	Wild-type from the colony
	000659 C3H/HeJ
Considerations for Choosing Controls
USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains.
International - Control Pricing Information for Genetically Engineered Mutant Strains.

General Terms and Conditions

See Terms of Use

The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX^® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX^® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX^® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.

---

Ordering and Purchasing Information

      Purchasing Information
      JAX^® Mice Orders
      Surgical Services

Contact Information
Orders & Technical Support
Tel: 800.422.6423 or 207.288.5845
Fax: 207.288.6150
Technical Support Email Form

Terms of Use

Terms of Use

General Terms and Conditions

Contact information

General inquiries

Contracts Administration

phone:	207-288-6470
fax:	207-288-6655

JAX^® Mice & Services Conditions of Use

“Each recipient institution, including its employees and other researchers under its control (RECIPIENT), of mice or services using mice from The Jackson Laboratory (TJL) agrees that such mice, descendants of those mice derived by inbreeding or crossbreeding, including unmodified derivatives of those mice or their descendants (“MICE”) shall not be: (i) used for any purpose other than the internal research of the RECIPIENT, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services with respect to MICE. Acceptance of MICE from TJL shall be deemed agreement by RECIPIENT to these conditions, and departure from these conditions requires The Jackson Laboratory’s prior written authorization.”

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of MICE, products or services, The Jackson Laboratory will, at its option, provide credit or replacement for the MICE or product received or the services provided.

No Liability

In no event shall The Jackson Laboratory, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, products or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of The Jackson Laboratory, its agents or employees. In purchasing or receiving MICE, products or services from The Jackson Laboratory, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges The Jackson Laboratory from all such causes of action or damages, and further agrees to defend and indemnify The Jackson Laboratory from any costs or damages arising out of any third party claims.

MICE and biological materials are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to The Jackson Laboratory’s MICE, products and services. In addition, special terms and conditions of sale of certain MICE, products and services may be set forth separately in The Jackson Laboratory web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, products and services by The Jackson Laboratory, and by its licensees and distributors.

Acceptance of delivery of MICE, products or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on The Jackson Laboratory, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, products services by The Jackson Laboratory.